{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:28:46Z","timestamp":1791340126670,"version":"4.3.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2106,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["26461424"],"award-info":[{"award-number":["26461424"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","exphem.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.exphem.2016.05.001","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T23:07:32Z","timestamp":1463180852000},"page":"817-825.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis"],"prefix":"10.1016","volume":"44","author":[{"given":"Shinya","family":"Daitoku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuto","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Yurino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Nunomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2016.05.001_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2016.05.001_bib3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2016.05.001_bib4","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2016.05.001_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2016.05.001_bib7","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2016.05.001_bib8","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2016.05.001_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/bj3440281","article-title":"Calreticulin: one protein, one gene, many functions","volume":"344","author":"Michalak","year":"1999","journal-title":"Biochem J"},{"key":"10.1016\/j.exphem.2016.05.001_bib10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/BJ20081847","article-title":"Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum","volume":"417","author":"Michalak","year":"2009","journal-title":"Biochem J"},{"key":"10.1016\/j.exphem.2016.05.001_bib11","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib12","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib13","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2016.05.001_bib16","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2014-01-547596","article-title":"Two faces of ET: CALR and JAK2","volume":"123","author":"Chao","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib17","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00277-014-2151-8","article-title":"Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia","volume":"93","author":"Chen","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2016.05.001_bib18","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2013.382","article-title":"Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis","volume":"28","author":"Chi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2016.05.001_bib19","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","article-title":"Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia","volume":"124","author":"Finazzi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib20","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc1400499","article-title":"JAK inhibitor in CALR-mutant myelofibrosis [correspondence]","volume":"370","author":"Passamonti","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2016.05.001_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/ejh.12389","article-title":"Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history","volume":"94","author":"Gangat","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2016.05.001_bib22","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/blood-2014-04-572040","article-title":"CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence","volume":"123","author":"Giona","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib23","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3324\/haematol.2014.109249","article-title":"Calreticulin mutations in Chinese with primary myelofibrosis","volume":"99","author":"Li","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2016.05.001_bib24","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.3324\/haematol.2014.109199","article-title":"Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients","volume":"99","author":"Qiao","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2016.05.001_bib25","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib26","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. AK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib27","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib28","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","article-title":"Distinct clinical characteristics in myeloproliferative neoplasms with calreticulin mutations","volume":"99","author":"Andrikovics","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2016.05.001_bib29","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib30","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2016.05.001_bib31","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1096\/fj.09-145482","article-title":"Calreticulin: non-endoplasmic reticulum functions in physiology and disease","volume":"24","author":"Gold","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.exphem.2016.05.001_bib32","doi-asserted-by":"crossref","first-page":"63ra94","DOI":"10.1126\/scitranslmed.3001375","article-title":"Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47","volume":"2","author":"Chao","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2016.05.001_bib33","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","article-title":"Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia","volume":"71","author":"Chao","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2016.05.001_bib34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2016.05.001_bib35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrc3171","article-title":"Programmed cell removal: a new obstacle in the road to developing cancer","volume":"12","author":"Chao","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2016.05.001_bib36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2005.08.032","article-title":"Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte","volume":"123","author":"Gardai","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2016.05.001_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1749-6632.2010.05740.x","article-title":"Surface-exposed calreticulin in the interaction between dying cells and phagocytes","volume":"1209","author":"Martins","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.exphem.2016.05.001_bib38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2016.05.001_bib39","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.coi.2008.05.007","article-title":"Immunogenic cancer cell death: a key-lock paradigm","volume":"20","author":"Tesniere","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.exphem.2016.05.001_bib40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2141.2010.08249.x","article-title":"JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation","volume":"150","author":"Oku","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2016.05.001_bib41","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1182\/blood-2012-02-408864","article-title":"Engulfment of hematopoietic stem cells caused by down-regulation of CD47 is critical in the pathogenesis of hemophagocytic lymphohistiocytosis","volume":"120","author":"Kuriyama","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib42","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.exphem.2010.09.008","article-title":"Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients","volume":"39","author":"Stein","year":"2011","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2016.05.001_bib44","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2016.05.001_bib45","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes","volume":"110","author":"Pang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2016.05.001_bib46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2741\/2692","article-title":"Macrophage activation and polarization","volume":"13","author":"Martinez","year":"2008","journal-title":"Front Biosci"},{"key":"10.1016\/j.exphem.2016.05.001_bib47","first-page":"246","article-title":"Functional phenotypes of macrophages and the M1-M2 polarization concept. Part I. Proinflammatory phenotype","volume":"77","author":"YSh","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.exphem.2016.05.001_bib48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2016.05.001_bib49","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1100\/2011\/213962","article-title":"Macrophage polarization in health and disease","volume":"11","author":"Cassetta","year":"2011","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.exphem.2016.05.001_bib50","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2016.05.001_bib51","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1172\/JCI33010","article-title":"STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice","volume":"117","author":"Huang","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2016.05.001_bib52","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/blood-2013-07-514208","article-title":"Loss of Stat1 decreases\u00a0megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs","volume":"123","author":"Duek","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.05.001_bib53","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","article-title":"Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling","volume":"18","author":"Chen","year":"2010","journal-title":"Cell Cancer Cell"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X16301266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X16301266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T05:16:17Z","timestamp":1654924577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X16301266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0301472X16301266"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2016.05.001","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2016.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}